{
    "organizations": [],
    "uuid": "716272db5ec5c2e20aa769c863edf851a1bed0c3",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ligand-earns-6-million-as-omniab-p/brief-ligand-earns-6-million-as-omniab-partner-out-licenses-antibody-projects-idUSASB0BZLF",
    "ord_in_thread": 0,
    "title": "BRIEF-Ligand Earns $6 Million As Omniab Partner Out-Licenses Antibody Projects",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 3, 2018 / 2:09 PM / Updated 10 minutes ago BRIEF-Ligand Earns $6 Million As Omniab Partner Out-Licenses Antibody Projects Reuters Staff \nJan 3 (Reuters) - Ligand Pharmaceuticals Inc: \n* LIGAND EARNS $6 MILLION AS OMNIAB PARTNER OUT-LICENSES ANTIBODY PROJECTS * SEES FY 2017 ADJUSTED EARNINGS PER SHARE $3.13 TO $3.16 \n* SEES FY 2017 REVENUE ABOUT $140 MILLION Source text for Eikon: Further company coverage:",
    "published": "2018-01-03T16:08:00.000+02:00",
    "crawled": "2018-01-03T16:22:01.020+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "earns",
        "million",
        "omniab",
        "partner",
        "antibody",
        "project",
        "reuters",
        "staff",
        "jan",
        "reuters",
        "ligand",
        "pharmaceutical",
        "inc",
        "ligand",
        "earns",
        "million",
        "omniab",
        "partner",
        "antibody",
        "project",
        "see",
        "fy",
        "adjusted",
        "earnings",
        "per",
        "share",
        "see",
        "fy",
        "revenue",
        "million",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}